Investment Analysts’ Weekly Ratings Changes for Bausch Health Companies (BHC)

Bausch Health Companies (NYSE: BHC) recently received a number of ratings updates from brokerages and research firms:

  • 5/8/2020 – Bausch Health Companies had its price target lowered by analysts at Royal Bank of Canada from $25.00 to $24.00. They now have a “sector perform” rating on the stock.
  • 5/8/2020 – Bausch Health Companies had its price target lowered by analysts at Cfra from $28.00 to $18.00. They now have a “hold” rating on the stock.
  • 5/8/2020 – Bausch Health Companies had its price target lowered by analysts at SunTrust Banks, Inc. from $25.00 to $24.00. They now have a “buy” rating on the stock.
  • 5/1/2020 – Bausch Health Companies was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 4/30/2020 – Bausch Health Companies had its price target raised by analysts at Wells Fargo & Co from $17.00 to $18.00. They now have an “equal weight” rating on the stock.
  • 4/28/2020 – Bausch Health Companies had its price target lowered by analysts at Royal Bank of Canada from $26.00 to $25.00. They now have a “sector perform” rating on the stock.
  • 4/28/2020 – Bausch Health Companies had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
  • 4/24/2020 – Bausch Health Companies is now covered by analysts at Citigroup Inc. They set a “buy” rating and a $30.00 price target on the stock.
  • 4/23/2020 – Bausch Health Companies had its price target lowered by analysts at Jefferies Financial Group Inc from $35.00 to $27.00. They now have a “buy” rating on the stock.
  • 4/3/2020 – Bausch Health Companies was downgraded by analysts at TheStreet from a “c-” rating to a “d+” rating.
  • 4/2/2020 – Bausch Health Companies was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating.
  • 3/23/2020 – Bausch Health Companies had its price target lowered by analysts at Wells Fargo & Co from $32.00 to $17.00. They now have an “equal weight” rating on the stock.
  • 3/23/2020 – Bausch Health Companies had its price target lowered by analysts at HC Wainwright from $60.00 to $50.00. They now have a “buy” rating on the stock.

Shares of NYSE BHC traded down $0.41 during trading hours on Friday, hitting $17.77. The stock had a trading volume of 52,308 shares, compared to its average volume of 7,090,334. The company has a market capitalization of $6.28 billion, a P/E ratio of -3.32, a P/E/G ratio of 0.46 and a beta of 1.27. The firm’s 50-day moving average price is $16.60 and its two-hundred day moving average price is $23.75. Bausch Health Companies Inc has a 52 week low of $11.15 and a 52 week high of $31.97.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.88 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.88. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $2.03 billion. Bausch Health Companies had a positive return on equity of 84.58% and a negative net margin of 21.96%. The firm’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.03 EPS. Equities research analysts anticipate that Bausch Health Companies Inc will post 3.74 earnings per share for the current fiscal year.

In related news, EVP Christina Ackermann bought 4,390 shares of Bausch Health Companies stock in a transaction that occurred on Tuesday, March 10th. The stock was purchased at an average cost of $18.25 per share, for a total transaction of $80,117.50. Following the acquisition, the executive vice president now owns 87,245 shares in the company, valued at $1,592,221.25. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Schutter Richard U. De bought 5,000 shares of Bausch Health Companies stock in a transaction that occurred on Tuesday, March 3rd. The stock was bought at an average price of $23.08 per share, with a total value of $115,400.00. Following the completion of the acquisition, the director now owns 279,250 shares in the company, valued at approximately $6,445,090. The disclosure for this purchase can be found here. In the last three months, insiders purchased 3,680,446 shares of company stock valued at $61,478,451. 12.14% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Guggenheim Capital LLC lifted its holdings in shares of Bausch Health Companies by 4.4% during the fourth quarter. Guggenheim Capital LLC now owns 12,546 shares of the company’s stock worth $375,000 after buying an additional 532 shares during the last quarter. Crossmark Global Holdings Inc. increased its position in shares of Bausch Health Companies by 3.1% during the fourth quarter. Crossmark Global Holdings Inc. now owns 20,784 shares of the company’s stock valued at $622,000 after purchasing an additional 620 shares during the period. Greatmark Investment Partners Inc. increased its position in shares of Bausch Health Companies by 4.8% during the fourth quarter. Greatmark Investment Partners Inc. now owns 17,731 shares of the company’s stock valued at $531,000 after purchasing an additional 806 shares during the period. Orion Portfolio Solutions LLC bought a new stake in shares of Bausch Health Companies during the fourth quarter valued at approximately $30,000. Finally, Baird Financial Group Inc. increased its position in shares of Bausch Health Companies by 1.0% during the first quarter. Baird Financial Group Inc. now owns 105,700 shares of the company’s stock valued at $1,638,000 after purchasing an additional 1,000 shares during the period. Hedge funds and other institutional investors own 62.99% of the company’s stock.

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Further Reading: Market Indexes

Receive News & Ratings for Bausch Health Companies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies Inc and related companies with MarketBeat.com's FREE daily email newsletter.